With a packed pipeline of drug candidates targeting multiple markers of cancer, Bayer AG signed on for a new project, this ...

The largest genome-wide association study to date of myalgic encephalomyelitis/chronic fatigue syndrome has identified eight ...

Fosun Pharmaceutical Co. Ltd. subsidiary Fosun Pharma Industrial is out-licensing its phase II dipeptidyl peptidase 1 inhibitor, XH-S004, to newco Expedition Therapeutics Inc. in a deal worth up to ...

Boehringer Ingelheim GmbH’s zongertinib enters the market as the first oral HER2-targeted therapy for patients with non-small ...

Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...

In less than two weeks, Setpoint Medical Inc. mastered the power serve with the first approval of a neuroimmune modulation device to manage rheumatoid arthritis, followed by a $25 million second ...

Syntara Ltd.’s stock plummeted 52% on news that the FDA recommended an additional phase IIb trial following a type C meeting ...

Phosphorylation of the protein Tau is a key post-translational feature in tauopathies like Alzheimer’s disease (AD), which ...

Chronic infection with the parasitic protozoan Cryptosporidium can cause debilitating diarrhea and lead to cognitive ...

A research team from Pusan National University has developed a novel deep learning model coined Moglo-Net, designed to enable three-dimensional reconstruction of images from hand-held ultrasound ...

Eleven pages is relatively short for a modern U.S. FDA draft guidance, but two trade associations nonetheless had questions about the FDA draft for transfers of 510(k) devices, such as how the agency ...

Temple University has described compounds acting as antioxidants and nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators reported to be useful for the treatment of Alzheimer’s ...